ADC Therapeutics reports $20M in revenue with critical clinical readouts imminent
ADC Therapeutics (NYSE:ADCT), a commercial-stage biotechnology company specializing in antibody-drug conjugates (ADCs), reported its financial results for the first quarter of 2026.























